Exscientia PLC (EXAI)
5.03
+0.27
(+5.67%)
USD |
NASDAQ |
Jun 14, 16:00
5.00
-0.03
(-0.60%)
After-Hours: 20:00
Exscientia Enterprise Value: 410.49M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | 410.49M |
| June 13, 2024 | 376.36M |
| June 12, 2024 | 415.54M |
| June 11, 2024 | 447.13M |
| June 10, 2024 | 418.07M |
| June 07, 2024 | 454.72M |
| June 06, 2024 | 519.17M |
| June 05, 2024 | 538.12M |
| June 04, 2024 | 502.74M |
| June 03, 2024 | 459.77M |
| May 31, 2024 | 444.61M |
| May 30, 2024 | 399.11M |
| May 29, 2024 | 364.99M |
| May 28, 2024 | 376.36M |
| May 24, 2024 | 367.52M |
| May 23, 2024 | 372.57M |
| May 22, 2024 | 400.38M |
| May 21, 2024 | 368.78M |
| May 20, 2024 | 430.71M |
| May 17, 2024 | 431.97M |
| May 16, 2024 | 423.12M |
| May 15, 2024 | 423.12M |
| May 14, 2024 | 405.43M |
| May 13, 2024 | 395.32M |
| May 10, 2024 | 357.41M |
| Date | Value |
|---|---|
| May 09, 2024 | 400.38M |
| May 08, 2024 | 366.25M |
| May 07, 2024 | 402.90M |
| May 06, 2024 | 406.69M |
| May 03, 2024 | 364.99M |
| May 02, 2024 | 418.07M |
| May 01, 2024 | 424.39M |
| April 30, 2024 | 400.38M |
| April 29, 2024 | 358.67M |
| April 26, 2024 | 284.11M |
| April 25, 2024 | 279.06M |
| April 24, 2024 | 296.75M |
| April 23, 2024 | 328.34M |
| April 22, 2024 | 311.91M |
| April 19, 2024 | 310.65M |
| April 18, 2024 | 325.81M |
| April 17, 2024 | 320.76M |
| April 16, 2024 | 311.91M |
| April 15, 2024 | 325.81M |
| April 12, 2024 | 363.10M |
| April 11, 2024 | 395.32M |
| April 10, 2024 | 375.35M |
| April 09, 2024 | 396.19M |
| April 08, 2024 | 401.87M |
| April 05, 2024 | 386.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-122.41M
Minimum
Dec 27 2022
2.901B
Maximum
Oct 01 2021
604.71M
Average
367.55M
Median
Enterprise Value Benchmarks
| Akero Therapeutics Inc | 789.38M |
| Adaptimmune Therapeutics PLC | 114.47M |
| Biodexa Pharmaceuticals Plc | 1.287M |
| Verona Pharma PLC | 1.021B |
| NuCana PLC | -9.447M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.65M |
| Revenue (Quarterly) | 6.710M |
| Total Expenses (Quarterly) | 42.06M |
| EPS Diluted (Quarterly) | -0.2156 |
| Gross Profit Margin (Quarterly) | -40.02% |
| Profit Margin (Quarterly) | -397.1% |
| Earnings Yield | -25.94% |
| Normalized Earnings Yield | -26.03 |